帕金森病中氧化压力的来源:途径和治疗影响
Yordan Yordanov1, Denitsa Stefanova1, Magdalena Kondeva-Burdina1
1Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria.
Antioxidants (Basel, Switzerland)
|February 27, 2026
概括
氧化应激是帕金森病 (PD) 进展的关键因素,它将各种侮辱与神经元损失联系起来. 未来的疗法必须解决疾病异质性和患者特异性的脆弱性,以获得有效的治疗.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特征是多巴胺能神经元损失.
- 氧化应激是一种常见的途径,将遗传和环境因素与PD病变发生联系起来.
- 线粒体功能障碍,溶酶体损伤和炎症有助于PD的氧化还原失衡.
研究的目的:
- 审查PD病理在氧化应激上的趋同.
- 概述PD的氧化还原向治疗策略.
- 讨论病因异质性对治疗结果的影响.
主要方法:
- 关于PD病理和氧化应激路径的文献综合.
- 对影响细胞质量控制和炎症的PD相关基因的概述.
- 对氧化还原向疗法的临床前和临床数据的分析.
主要成果:
- 不同的PD侮辱趋于过度反应性氧物种生成和氧化还原失衡.
- 许多氧化还原向剂在临床前模型中表现有前途,但在临床试验中面临挑战.
- 病因异质性影响目标参与和临床疗效.
结论:
- 针对氧化应激路径为PD疾病修饰提供了一个有希望的途径.
- 未来的干预措施需要机械洞察力和适应患者特定的氧化还原漏洞.
- 用亚型丰富的试验和组合方法可以提高治疗成功率.
相关概念视频
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.9K
Electron Transport Chain: Complex I and II
19.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.2K
Phase I Oxidative Reactions: Overview
893
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
893


